Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases

• Published in: Doklady. Biochemistry and biophysics Vol. 517; no. 1; pp. 207 - 213
• Main Authors: Panafidina, T. A., Verizhnikova, Zh. G., Avdeeva, A. S., Popkova, T. V., Nasonov, E. L.
• Format: Journal Article
• Language: English
• Published: Moscow Pleiades Publishing 01.08.2024; Springer Nature B.V
• Subjects: Adaptor Proteins, Signal Transducing - immunology; Adult; Antibodies, Antinuclear - blood; Antibodies, Antinuclear - immunology; Antinuclear antibodies; Antinuclear factor; Autoantibodies; Biochemistry; Biological and Medical Physics; Biomarkers - blood; Biomedical and Life Sciences; Biophysics; Clinical Relevance; Diagnosis; Female; Humans; Immunofluorescence; Life Sciences; Male; Middle Aged; Molecular Biology; Rheumatic diseases; Rheumatic Diseases - immunology; Transcription Factors - immunology; immunoinflammatory rheumatic diseases; anti-DFS70; indirect immunofluorescence assay on HEp-2 cells; antinuclear antibodies
• ISSN: 1607-6729; 1608-3091; 1608-3091
• DOI: 10.1134/S1607672924700911

The relevance of the problem of immunoinflammatory rheumatic diseases (IIRD) for modern medicine is determined by their high prevalence in the population, the difficulty of early diagnosis, the rapid development of disability and poor life prognosis. Recent data on the significance of anti-DFS70 have opened up new possibilities for optimizing the step-by-step diagnosis of IIRD. The detection of these antibodies can help in the interpretation of a positive result for antinuclear antibodies (ANA) by indirect immunofluorescence assay on HEp-2 cells (IIFA-HEp-2) in the absence of autoantibodies specific for IIRD. Detection of anti-DFS70 in antinuclear factor (ANF) seropositive patients without clinical and/or serological markers characteristic of a certain disease from the IIRD group can be considered as a potential marker that excludes this group of diseases.